Coronavirus infection

4 trials MedDRA PT
4 Registered trials
0 Recruiting
3 Unique sponsors
4 Unique IMPs
4 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
J Anti-infectives (ATC J) 1
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Monoclonal antibody (primate) 1 substance
Supportive / diluent 1 substance
Phase III: 1 Phase I/II: 1 Phase I: 2

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • AstraZeneca AB Commercial
    CILGAVIMAB; SIPAVIBART
    2024-512554-15-00 6 countries 2023 n=533
    Ended

Phase I/II

1 trial
  • Osivax Commercial
    OVX033; SODIUM CHLORIDE
    2024-517396-20-00 1 country n=240
    Pending

Phase I

2 trials
  • Osivax Commercial
    IMP not specified
    2023-506396-94-00 1 country 2024 n=48
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    IMP not specified
    2023-505041-52-00 1 country 2023 n=128
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Osivax Commercial 2 Phase I, Phase I/II 0
Regeneron Pharmaceuticals Inc. Commercial 1 Phase I 0
AstraZeneca AB Commercial 1 Phase III 0
New trials by year
2023
2
2024
1
← All indication landscapes